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ABSTRACT 
 
 
Introduction 
Dolutegravir (DTG) combined with darunavir/cobicistat (DRV/COBI) is a promising NRTI 
sparing and/or salvage strategy for the treatment of HIV-1 infection.  
Methods 
This phase 1, open label, 57 day, cross over, pharmacokinetic (PK) study, enrolled 
healthy volunteers aged 18-65 years, who were randomized to one of two groups. Group 
one received DTG 50mg once daily (OD) D for 14 days followed by a 7 day wash out, a 
14 day DTG/DRV/COBI OD co-administration period followed by a 7 day wash out and 
finally a 14 day period of DRV/COBI 800/150mg OD. Group 2 followed the same 
sequence starting with DRV/COBI and concluding with DTG. Each group underwent 
intensive PK sampling over 24hrs on day 14 of each drug period and DTG/DRV/COBI 
concentrations were measured by validated LC-MS/MS methods. 
Results 
Twenty participants completed all PK phases. Thirteen were female and median age 
and BMI were 33.5yrs and 27kg/m2. DTG geometric mean ratios (GMR, 
DTG+DRV/COBI versus DTG alone) and 90% confidence intervals (CI) for Cmax, AUC0-
24 and C24h were 1.01 (0.92-1.11), 0.95 (0.87-1.04) and 0.9 (0.8-1.0). DRV GMR 
(DRV/COBI+DTG versus DRV/COBI alone) and 90%CI for Cmax, AUC0-24 and C24h were 
0.90 (0.83-0.98), 0.93 (0.86-1.00) and 0.93 (0.78-1.11). No grade 3 or 4 adverse events 
or laboratory abnormalities were observed.  
Conclusions 
Concentrations of DTG during co-administration with DRV/COBI decreased by 10% or 
less and those of DRV remained unchanged suggesting this combination can be 
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prescribed safely in the treatment of HIV-1 at standard doses, including in patients 
harbouring resistance that benefit from optimal antiretroviral exposures. 
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INTRODUCTION 
 
Triple-drug antiretroviral (ARV) therapy has been the cornerstone of HIV treatment since 
1996, leading to unprecedented success in disease control in people living with HIV 
(PLWH). With increasingly potent agents, there has, in recent years, been a drive to 
investigate treatment simplification strategies that aim to lessen toxicity, drug 
interactions and cost through reducing the number of drugs taken. 1 Current available 
evidence favours dual therapy over monotherapy and is most reasuring in suppressed 
patients who have maintained virological suppression for at least six months on triple 
therapy. 2 
Dolutegravir (DTG) and boosted darunavir (DRV/b) are both strong players in this 
paradigm shift, featuring individually in most of the recent dual combinations studied 2. 
They are the agents with the highest potency and resistance barrier within their 
respective classes and overall 3, 4 and are therefore also important to salvage therapy in 
patients experiencing treatment failure and harbouring multi-class drug resistances. 5, 6 
DTG and DRV/ritonavir (RTV) have individually been paired with lamivudine (3TC) in 
dual therapy studies, with promising data in treatment naïve and in virologically 
suppressed patients. 7-12 DTG combined with rilpivirine (RPV) has also been studied in 
a large randomized, open-label, phase III trial (SWORD 1&2) and in smaller cohort 
studies, 13-15 showing high efficacy and cost savings 16 when used as maintenance 
therapy (albeit with slightly higher discontinuation rates secondary to AEs compared to 
a control standard treatment arm (3% versus 1%)).   
However, these options are not appropriate in the context of NRTI-related long-term 
toxicities and/or NRTI/NNRTI-associated resistance mutations. 17 As an NRTI/NNRTI-
sparing strategy, the combination of DTG and DRV/b can play a key role in this setting 
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especially that both agents have a high affinity for their target enzymes 18, 19 and together 
offer convenience, simplicity, potency and a high genetic barrier. 20 
Two cohort studies have been published on the use of DTG/DRV/RTV in difficult to treat 
patients. 21, 22 In Canada, Wheeler et al demonstrated maintenance of viral suppression 
at 12 months and high tolerability in 13 HIV patients with primary transmitted thymidine 
analogue mutation (TAM) resistance, who switched from a complex salvage multi-drug 
regimen to DTG/DRV/RTV. 21 Similarly, in Italy, Capetti et al followed 130 patients, with 
a current or past history of virological failure and documented viral resistance to one to 
five ARVs, who switched to DTG/DRV/RTV for simplification or rescue therapy. At the 
48-week follow up, subjects with active HIV replication dropped from 40% at baseline to 
6.1% and the metabolic impact was favourable. 22 A single-point pharmacokinetic (PK) 
analysis in a subgroup of this study (32 subjects) confirmed adequate median minimum 
concentrations (C24h) for both drugs (DTG 579 ng/mL; DRV 3007 ng/mL). The DUALIS 
study is a large, prospective, interventional, randomized, controlled study set up to 
assess the safety and efficacy of a once-daily (OD) DTG with DRV/RTV OD 
maintenance therapy. Whilst, recruitment is ongoing, an intensive PK sub-study over 12 
hours has been published and describes all steady-state PK parameters for both drugs 
during co-administration (median maximum concentration (Cmax) were 3427 ng/mL for 
DTG and 6170 ng/mL for DRV, C12h 637 ng/mL for DTG and 1245 ng/mL for DRV and 
area under the curve (AUC0-12) were 26809 ng*h/mL for DTG and 49920 ng*h/mL for 
DRV), C24h was not measured. 23 
PK data for DTG coadministration with DRV/cobicistat (COBI) are, however, very limited 
to date. COBI 24 is a newer, approved alternative pharmacological booster to RTV, which 
may be preferable in some patients. It has a lower potential for drug interactions than 
RTV, due to its more selective inhibition of CYP3A and lower likelihood for enzymatic 
 6 
induction. 25 DTG C24h doubled, when measured at least 10 days after switching from 
DRV/RTV to DRV/COBI in a therapeutic drug monitoring (TDM) survey of HIV infected 
subjects (n=12), 26 in contrast to a 38% decrease seen with DRV/RTV twice daily in 
healthy volunteers 27.  
No intensive PK data have been published to date on DTG/DRV/COBI co-
administration. We, therefore, aimed to describe the steady-state PK of DTG 50 mg 
(Tivicay®) once daily (OD) and of fixed dose DRV/COBI 800/150 mg (Rezolsta®) OD, 
over 24 hours when co-administered in healthy volunteers. 
 
METHODS 
 
Participants 
Eligible participants were male and non-pregnant and non-lactating female healthy 
volunteers aged between 18 and 65 years with a BMI between 18 and 35 kg/m2. 
Participants were excluded if they had any significant acute or chronic medical illness; 
abnormal physical examination, ECG or clinical laboratory determinations; positive 
screens for HIV, hepatitis B or C; current or recent (within three months) gastrointestinal 
disease; clinically relevant alcohol or drug use that the investigator felt would adversely 
affect compliance with trial procedures; exposure to any investigational drug or placebo 
within three months of the first dose of the study drug; use of any other drugs, including 
over the counter medications and herbal preparations, within two weeks of the first dose 
of the study drug; and previous allergy to any of the constituents of the pharmaceuticals 
administered during the trial. 
 
Study design 
 7 
The study design is illustrated in figure 1. This was a phase 1, open label, 57 day, 
crossover PK study carried out at the Clinical Trial Unit of the St. Stephen’s Centre, 
Chelsea, and Westminster Hospital, London, United Kingdom.  
At screening, participants had a clinical assessment and routine laboratory 
investigations performed. After successful screening, eligible participants were 
randomized to one of two groups. Group one received DTG 50 mg OD for 14 days 
followed by a 7 day wash out (day 15 – 21). From day 22 to 35, in the coadministration 
period, they received DTG 50 mg OD plus DRV/COBI 800/150 mg OD for 14 days, 
which was followed by a 7 day wash out (day 36 – 42) and finally a 14 day period of 
DRV/COBI 800/150 mg OD ensued. Group 2 followed the same structured sequence 
but started with DRV/COBI 800/150 mg OD and concluded with DTG 50 mg OD. The 
safety and tolerability of study medications were evaluated throughout the trial (on days 
7, 28, 49, PK days and at follow-up) using the NIAID Division of AIDS table for grading 
the severity of adult and pediatric adverse events to characterize abnormal findings, vital 
signs, physical examinations and clinical laboratory investigation (published 2004). 
Each group underwent intensive PK sampling on study days 14, 35 and 56 to measure 
plasma concentrations of DTG and/or DRV/COBI at 0 (pre-dose), 2, 4, 8, 12 and 24 
hours post dose. On the PK days, study staff witnessed study medication intake with a 
standardized breakfast (626 kcal) and 240 mL of water. 
 
Analytical and PK methods 
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at 
each time-point, immediately inverted several times and then kept on ice or refrigerated 
until centrifugation. Within 30 minutes of blood collection, each blood sample was 
centrifuged for 10 min at 2000 g at 4C. Plasma was then aliquoted equally into three 2.0 
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mL tubes (Sarstedt, Germany) and stored at -20C. 
Samples were shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The 
laboratory is Good Clinical Laboratory Practice-accredited and participates in an 
external quality assurance scheme (KKGT, the Netherlands).  
 
Quantification of dolutegravir, darunavir, and cobicistat 
Concentrations of DTG, DRV and COBI in plasma were measured using validated high-
pressure liquid chromatography–tandem mass spectrometry methods as previously 
described (HPLC MS/MS). 28, 29 The lower limits of quantification (LLQ) for plasma DTG 
was 0.75 ng/mL, 15 ng/mL for DRV and 10 ng/mL for COBI. For concentrations below 
the assay limit of quantification, a value of one-half of the quantification limit was used. 
Accuracy (percentage bias) was between 98.0% and 104.6% (DTG) 94.2% and 101.2% 
(DRV) and 92.3% and 104.0% (COBI), and precision was between 4.6% and 6.2% 
(DTG), 4.4% and 6.0% (DRV) and 3.1% and 6.5% (COBI). 
 
Data analysis 
The calculated PK parameters for plasma DTG, DRV and COBI were C24h, Cmax and 
AUC from 0 to 24 hours (AUC0–24). All PK parameters were calculated using actual blood 
sampling time and non-compartmental modeling techniques (WinNonlin Phoenix, 
version 6.1; Pharsight, Mountain View, CA). Descriptive statistics, including geometric 
mean (GM) and 95% confidence intervals (95% CI) were calculated for DTG, DRV and 
COBI plasma PK parameters. Each drug PK parameter during the co-administration 
period was compared to the unaccompanied drug PK parameter by calculating GM 
ratios (GMR) and 90% CI (co-administered/alone). 
Inter-individual variability in drug PK parameters was expressed as a percentage 
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coefficient of variation [CV, (standard deviation/mean)×100]. 
Since both COBI and DTG are associated with a small rise in creatinine through MATE1 
and OCT2 inhibition respectively, we evaluated the statistical significance of the 
changes in creatinine from baseline using the two-sided Wilcoxon signed-rank test for 
paired samples. 
 
Statistical power  
This is an exploratory study and, as such, no formal sample size calculation was 
performed. Twenty (20) participants completing the study was deemed appropriate to 
allow for relevant conclusions, as is standard for PK studies. 
 
Ethics 
The study protocol was approved by the Surrey Borders Research Ethics Committee 
and by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United 
Kingdom. The study was conducted according to Good Clinical Practice and the 
Declaration of Helsinki (NCT03094507). 
 
RESULTS 
 
Study Population 
Twenty-five healthy volunteers were screened, 21 attended baseline and 20 completed 
all PK phases (eleven in group 1 and 9 in group 2; one subject withdrew for personal 
reasons). Median age was 33.5 years (range 24-63), 13 participants were female and 
median body mass index (BMI) was 27 (range 20-31) kg/m2. Thirteen subjects described 
themselves as Caucasian, six as Black African/Caribbean and one as White and African.  
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DTG, DRV and COBI plasma pharmacokinetics 
Table 1 summarizes the PK parameters of DTG and DRV/COBI when administered 
alone or together in the co-administration phase, in both groups combined. 
Dolutegravir plasma pharmacokinetics 
Figure 2 illustrates the DTG GM plasma concentration versus time curves with and 
without DRV/COBI, in relation to DTG’s protein adjusted (PA) 90% inhibitory 
concentration (IC90) for wild type virus (64 ng/mL). 30 DTG geometric mean ratios (GMR, 
DTG+DRV/COBI versus DTG alone) and 90% confidence intervals (CI) for Cmax, AUC0-
24 and C24h were 1.01 (0.92-1.11), 0.95 (0.87-1.04) and 0.9 (0.8-1.0). No differences 
were seen between group 1 and 2.  
The inter-individual variability in DTG values was between 23 and 40% when 
administered alone and between 28 and 48% during co-administration with DRV/COBI. 
Darunavir plasma pharmacokinetics 
Figure 3 shows the DRV GM plasma concentration versus time curves with and without 
DTG in relation to DRV’s PA-IC90 (200 ng/mL). 31 DRV GMR (DRV/COBI+DTG versus 
DRV/COBI alone) and 90% CI for Cmax, AUC0-24 and C24h were 0.90 (0.83-0.98), 0.93 
(0.86-1.00) and 0.93 (0.78-1.11) and for COBI Cmax, AUC0-24 and C24h were 0.96 (0.89-
1.04), 0.98 (0.88-1.08) and 0.98 (0.79-1.22). The inter-individual variability in DRV 
values was between 31 and 52% when administered alone and between 20 and 53% 
during co-administration with DTG. 
 
C24h remained seven to 32 fold above the PA-IC90 (64 ng/mL) 30 for DTG and one and a 
half to 11 fold above the PA-IC90 (200 ng/mL) 31 for DRV in all subjects (except for one 
participant with a DRV C12h of 1428 ng/mL but C24h 185 ng/mL).  
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Safety and tolerability 
The studied drugs were well tolerated, with no grade 3 or 4 side effects or laboratory 
abnormalities. Median (IQR) creatinine at baseline was 67 μmol/L (63-71), during 
DRV/COBI adminstration 70 μmol/L (65-74), during DTG adminstration 76 μmol/L (69-
81) and during coadministration 74.5 μmol/L (70-79.5). The difference between baseline 
and during co-administration was significant (T=2.5, p<0.01), which was driven by DTG. 
However, adding DRV/RTV to DTG did not change creatinine significantly (P>0.05), 
whilst adding DTG to DRV/RTV did (T=29.5, p<0.01).  
 
DISCUSSION 
 
We characterised the steady state PK of standard dose DTG co-administered with 
DRV/COBI over 24 hours in healthy volunteers. The changes in DTG PK parameters 
during co-administration compared to DTG administered alone were minimal. DTG C24h 
decreased by 10%, whilst AUC decreased by 5% and Cmax remained unchanged. DRV 
concentrations also decreased by less than 10%. DTG and DRV concentrations 
remained manifold above the PA-IC90 for wild type virus in all participants at all time 
points, suggesting that the combination of DTG and DRV/COBI can be prescribed safely 
in the treatment of HIV-1, including in patients harbouring resistance that benefit from 
optimal antiretroviral exposures. In contrast, DTG C24h had decreased by 38% when co-
administered with DRV/RTV (twice daily) in early DTG drug interaction studies, which 
was not deemed clinically significant (Cmax decreased by 11% and AUC 22%; 
participants received multi-dose DTG 30 mg, administered with food). 27 
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Our findings are in agreement with Gervasoni et al., who showed a doubling of DTG 
C24h in HIV patients who switched from DRV/RTV to DRV/COBI. 26 DTG is primarily 
metabolised by UDP-glucuronosyltransferase-1A1 (UGT1A1) and is only a minor 
substrate for cytochrome P450 (CYP) 3A4. 32 Whilst both COBI and RTV are potent 
CYP3A4 inhibitors, unlike RTV, COBI does not induce glucoronidation (or any CYP 
enzymes), 33 which is likely to explain the difference in effect on DTG PK seen between 
the two pharmacological boosters. Interestingly, Gervasoni et al. commented on the 
possibility that their observed PK interaction between DTG and the boosting agents may 
be driven at least in part by increased DTG absorption mediated by a higher degree of 
inhibition of COBI on intestinal efflux transporters (P-Glycoprotein, PGP, and Breast 
Cancer Resistant Protein, BCRP), of which DTG is a know substrate. 26, 33 As no rise in 
DTG Cmax was seen in our study, our results would suggest the inhibitory effect of COBI 
on these transporters is only a limited in vivo, at least in the context of DRV.  
 
DTG does not induce or inhibit CYP enzymes, therefore effects on DRV and COBI 
(which are mainly metabolized by CYP3A4) were not expected during coadministration 
with DTG.  
 
Interestingly, the PK parameters of DTG in our study were, overall, lower than seen in 
Min et al.’s study (also healthy volunteers, n=8, food intake not specified) when 
administered alone and lower than in the Gervasoni et al. study when co-administered 
with COBI, highlighting the importance of describing intra-individual effect in drug 
interaction studies.  
Serum creatinine concentrations significantly increased from baseline during DTG 
administration, but no significant increment was recorded when DRV/COBI was added 
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to DTG, which is consistent with previous observations that administration may not result 
in additive renal toxicity at least in the short-term. 26, 34 
There are limitations in our study. Subjects were healthy volunteers and conclusions 
cannot be fully drawn in HIV infected participants. In licencing trials, DTG concentrations 
appeared generally lower in HIV infected participants than in healthy volunteers. 30 
Indeed, discrepancies in antiretroviral drug PK between healthy volunteers and people 
living with HIV have been previously described  (particularly for the protease inhibitors 
to date). 35 It thought such differences are related to physiological variability in several 
parameters between the two populations, including enzyme activity and a-1-acid 
glycoprotein expression. 35 Similarly, pharmacodynamics deductions cannot be drawn; 
however, previous cohort studies have reported good efficacy of DTG/DRV/COBI in 
small groups of HIV infected subjects.  
The strengths of our study lie in its prospective, controlled and crossover design, which 
allowed an analysis of intra-individual effect. Additionally the study population was 
appropriately diverse in gender, ethnicity and age. 
 
In conclusion, we investigated the intra-individual variance in DTG and DRV/COBI PK 
parameters when they are administered together compared to alone. Our results 
suggest that no dose adjustment is required in either agents and that this combination 
can be prescribed safely in the treatment of HIV-1, including in patients harbouring 
resistance.  
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TABLES AND FIGURES 
 
Table 1: Dolutegravir (DTG), darunavir (DRV) and cobicistat (COBI) steady state 
pharmacokinetic (PK) parameters, expressed as geometric mean (GM), 90% 
confidence intervals (CI), coefficient of variation (CV) and GM Ratios (GMR, alone/co-
administered). 
Cmax: maximum concentrations, AUC: area under the curve, C24h: concentration 
measured 24 hours post-dose. 
Figure 1: Diagram illustrating study design. 
Figure 2: GM dolutegravir concentrations over 24 hours with and without DRV/COBI. 
GM: geometric mean, DTG: dolutegravir, DRV: darunavir, COBI: cobicistat. IC90: (protein 
adjusted) inhibitory concentration. 
Figure 3: GM darunavir concentrations over 24 hours with and without dolutegravir 
GM: Geometric Mean, DTG: dolutegravir, DRV: darunavir, COBI: cobicistat, EC90: 
(protein-adjusted) effective concentration 
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 GM Cmax (90%CI)  (ng/mL) GM AUC0-24h(90% CI) (ng*h/mL) GM C24 (90% CI) (ng/mL) 
 Alone 
C
V
%
 
Combined 
C
V
%
 
GMR Alone 
C
V
%
 
Combined 
C
V
%
 
GMR Alone 
C
V
%
 
Combined 
C
V
%
 
GMR 
DTG 3398 (3087-3708) 23 3429  (3104-3755) 46 1.01 (0.92-1.11) 47669 (42377-52960) 28 45188 (40203-50174) 28 0.95 (0.87-1.04) 952 (795-1109) 40 852 (690-10145) 46 0.9 (0.80-1.00) 
DRV 5364 (4726-6003) 31 4821 (4455-5187) 20 0.90 (0.83-0.98) 63222 (55152-71291) 33 58864 (52978-64750) 26 0.93 (0.86-1.00) 1146 (891-1400) 52 1070 (817-1322) 53 0.93 (0.78-1.11) 
COBI 967 (868-1066) 27 929 (845-1014) 24 0.96 (0.89-1.04) 7829 (6865-8793) 32 7650 (6619-8682) 35 0.98 (0.88-1.08) 19 (10.4-28) 90 19 (6.7-31) 111 0.98 (0.79-1.22) 
 
 
  
Table 1: Dolutegravir (DTG), darunavir (DRV) and cobicistat (COBI) steady state pharmacokinetic (PK) parameters, expressed as geometric mean (GM), 90% confidence intervals (CI), coefficient of variation (CV) and GM 
Ratios (GMR, alone/co-administered). Cmax: maximum concentrations, AUC0-24h: area under the curve, C24h: concentration measured 24 hours post-dose. 
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